ArticleCancer medicine2026
Factors Associated With Rectal Spacer Use in Prostate Cancer Patients Receiving Radiation Therapy.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
BACKGROUND/
objectiveProstate cancer is a leading cause of cancer-related death among men in the United States. However, the influence of demographic, socioeconomic, regional, and treatment-related factors on rectal spacer use among men treated with radiation therapy remains largely unexplored in the literature. This study evaluated rectal spacer utilization among Medicare beneficiaries with prostate cancer by radiation therapy modality, region, race, income, and year.
methodsThe Medicare 5% Standard Analytical Files were used to identify men aged 65+ with prostate cancer who underwent treatment with intensity-modulated radiotherapy (IMRT), stereotactic body radiation (SBRT), brachytherapy, or proton therapy from 1/1/2017-12/31/2021. Patients were stratified by rectal spacer placement within 60 days pre-radiation therapy initiation.
resultsA total of 66,680 patients were identified (mean age 72.8 years, mean Charlson Comorbidity Index score 3.26, 80.7% White). Among this cohort, 17,940 patients (26.9%) received a rectal spacer. Spacer utilization increased significantly over time, from 6.8% in 2017 to 42.4% in 2021 (p < 0.05). Geographic variation was observed, with the highest utilization in the West (31.7%) and the lowest in the Northeast (23.6%). A greater proportion of White patients received rectal spacers than Black patients in all regions except the Northeast (West: 32.6% vs. 22.2%; South: 30.8% vs. 20.5%; Midwest: 24.4% vs. 15.5%; all p < 0.001), where the opposite was observed (31.8% vs. 22.2%; p < 0.001). Rectal spacer utilization increased with income, ranging from 20.9% in the lowest income quintile to 28.2% in the highest (p < 0.001). By treatment modality, utilization was highest among patients receiving proton therapy (59.0%), followed by SBRT (46.0%), brachytherapy (23.7%), and IMRT (20.6%).
conclusionsRectal spacer utilization increased significantly from 2017 to 2021, with the greatest relative increases among proton therapy patients and SBRT patients. Significant variations based on geographic region, race, and income highlight the complex interplay of these factors on treatment access and decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.